Farmaceutici Procemsa S.P.A.

What Farmaceutici Procemsa S.P.A. does

Farmaceutici Procemsa S.P.A. is an Italian Contract Development and Manufacturing Organization (CDMO) headquartered in Nichelino (Turin), founded in 1939, that develops and produces food supplements, probiotics, medical devices, and cosmetics exclusively on a third-party/private-label basis. The company operates from three Italian manufacturing sites — Via Vernea (7,740 sqm, headquarters, R&D, logistics, production), Via Mentana (3,040 sqm, registered office, production, transition warehouse, R&D lab), and a Central Logistic Centre inaugurated in May 2020 with 5,500 pallet spaces — together providing 9,370 pallet spaces across 2,100 sqm of warehousing and a dedicated ISO class 8 probiotic facility. Production covers tablets (single/double/triple layer, chewable, coated, effervescent, gastro-resistant, probiotic-based), hard gelatin and HPMC capsules, single-dose sachets/sticks/strips, powders and granulates, liquids (solutions, syrups, dispersions, suspensions, oils), and semisolid forms (emulsions, ointments, gels, medical devices in PE and aluminum tubes). Underlying the CDMO platform are eight proprietary technology families (LIMOR, IOR, MOR, multi-layer tablet, increased oral release, gastro-resistant, Tabgum, probiotic stability) plus proprietary raw materials ALFAMEL and ROSHIELD protected by three international patents each, and granted patents spanning Italy, EU, and US on propolis formulations, food emulsions, and anti-cellulite topical compositions.

The business model is pure B2B contract manufacturing and development: Procemsa charges manufacturing fees, formulation development, and dossier/regulatory support to multinational corporations, national brands, and e-commerce brands across Health & Wellbeing, Pharma, and Makeup & Skincare, exporting to 63 countries. The company does not sell under its own consumer brand. Customers benefit from an integrated service spanning idea generation, R&D, regulatory and scientific dossier development, ICH stability studies, production, packaging, and logistics. The firm holds a dense regulatory stack — GMP/FDA (registration 15721871314), ISO 9001, ISO 13485, ISO 14001, ISO 45001, IFS Food v6, NSF/ANSI 455-2, HALAL and BIOLOGIC on-demand — with manufacturing plants recognized by health authorities of Canada, UAE, Kuwait, Oman, Qatar, Iraq, Iran, Israel, Algeria, Benin, Jordan, Sudan, Lebanon, Yemen, and Bahrain.

Since Investindustrial acquired 70% in June 2019 (Sertorio family retaining 30%), Procemsa has executed an aggressive European CDMO roll-up: OFI Officina Farmaceutica Italiana (Dec 2020, Italy), Aakamp (Mar 2022, Germany), and a signed agreement for majority control of Master Pharm S.A. (Aug 2023, Poland). Post-Master Pharm, the group is projected to exceed €150M revenue across 8 plants and 700+ employees. Leadership transitioned on 21 July 2023, with Alessandro Sertorio moving to Non-Executive Chairman and Sagi Cohen — formerly Chairman of the Procemsa Board with senior board experience at 7-Eleven, Tnuva, Caesarstone, and Aran Packaging — installed as Group CEO. Filippo Sertorio continues as President of the Group and Chief Sustainability Officer; the group committed in 2022 to a Science Based Targets 23% absolute scope 1+2 GHG reduction by 2030 and received a Sustainability Award from Kon Group, Credit Suisse, and Forbes.

Name

Farmaceutici Procemsa S.P.A.

Legal name

Farmaceutici Procemsa S.p.A.

Website

https://procemsa.it

Company type

Private

Founded year

1939

Operating status

Operating

Headcount range

101–250 employees

Short description

Italian CDMO founded in 1939, developing and manufacturing food supplements, probiotics, medical devices, and cosmetics on a contract basis for multinational, national, and e-commerce brands across 63 countries from three Italian plants, now expanding into a pan-European group via acquisitions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311)

SIC

Food And Kindred Products (2000), Pharmaceutical Preparations (2834), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract pharmaceutical manufacturing
• Food supplement CDMO
• Medical device manufacturing
• Probiotic production services
• Cosmetic contract manufacturing

Headquarters

HQ city

Nichelino

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Procemsa operates exclusively as a CDMO (Contract Development and Manufacturing Organization), developing and producing Food Supplements, Medical Devices, Cosmetics, and Functional Foods for third parties. Revenue is generated through manufacturing fees, formulation development services, and product development across all solid and liquid pharmaceutical forms. The company offers comprehensive services from idea generation to logistics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Farmaceutici Procemsa S.p.A. operates as a B2B Contract Development and Manufacturing Organization (CDMO), developing and producing food supplements, probiotics, medical devices, cosmetics, and functional foods exclusively for third-party brands. The company provides comprehensive services spanning product formulation, R&D, production in multiple pharmaceutical forms (tablets, capsules, sachets, powders, liquids, and semi-solids), packaging, regulatory support, and logistics.

Product overview

Farmaceutici Procemsa S.P.A. is a Contract Development and Manufacturing Organization (CDMO) offering a comprehensive portfolio of health and wellness products for third parties. The core portfolio consists of Food Supplements, Probiotics, Medical Devices (Class I, II, III), and Cosmetics, supported by proprietary ingredients ALFAMEL and ROSHIELD. Production capabilities span multiple pharmaceutical forms including Tablets, Capsules, Sachets/Sticks/Strips, Powders/Granulates, Liquids, and Semisolid Forms. The company operates three manufacturing plants with dedicated areas for different product categories, including an independent probiotic production facility. Services include Private Label manufacturing and Functional Food development. The integrated quality system covers all stages from R&D through production and packaging, supported by specialized laboratories and equipment.

Differentiator

Problem solved

Functional benefit

Products and services

• Food Supplements

Quantifiable outcome

• Presence in 63 countries worldwide
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Six partnerships are on record, tiered core, minor and historical.

• Master Pharm S.A.coreStrategic or Co-development Partner · 16 August 2023Procemsa signed agreement to acquire majority stake in Master Pharm, a leading CDMO in Poland founded in 2002 and headquartered in Łódź. Master Pharm manufactures dietary supplements in tablets, soft gels, capsules, sachets and drops. The acquisition reinforces Procemsa's European presence and will bring group revenue to over €150 million with 8 plants and 700+ employees. Expected to close later in 2023.
• AakampcoreStrategic or Co-development Partner · 1 March 2022Procemsa acquired Aakamp in Germany in March 2022, expanding the group's manufacturing footprint to Germany as part of the consolidation strategy of the European CDMO market.
• OFI Officina Farmaceutica Italiana SpAcoreStrategic or Co-development Partner · 1 December 2020Procemsa acquired OFI in December 2020, establishing a leading group in contract manufacturing for food supplements, cosmetics, and medical devices. OFI became part of the Procemsa Group portfolio.
• OurvitaminorOthersOurvita is identified as the parent group of Procemsa, with Procemsa listed as 'Company part of Ourvita' on the Procemsa website.
• Doppel SpAhistoricalStrategic or Co-development PartnerHistorical affiliation with Doppel SpA from 2003 (Sertorio 60% - Doppel 40%), with ownership structure changing to Sertorio 75.3% - Doppel 24.7% in 2016. Procemsa returned to 100% Sertorio family ownership in 2018 before Investindustrial investment.
• Research InstitutionsminorStrategic or Co-development PartnerProcemsa collaborates with research institutions for exclusive raw materials development, including university studies for proprietary ingredients like ALFAMEL and ROSHIELD extracts.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aenova: Aenova is one of Europe's largest pharmaceutical and nutraceutical CDMOs, offering solid and semi-solid dosage form development and manufacturing across multiple sites in Germany, Italy, and Switzerland — directly comparable to Procemsa's pan-European CDMO model.
• Recipharm: Recipharm is a leading European CDMO (acquired by EQT in 2021) offering contract development and manufacturing of pharmaceuticals and consumer health products across multiple European sites, directly comparable in scale, regulatory scope, and customer mix to Procemsa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/policies/cookies
• Instagraminstagram.com/519522125107875
• LinkedInlinkedin.com/company/farmaceutici-procemsa-s.p.a.
• YouTubeyoutube.com/policies.google.com/privacy?hl=it
• Xhelp.twitter.com/it/rules-and-policies/twitter-cookies

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmaceutici Procemsa S.P.A.